Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma

Takahiro Higuchi; Syoutoku Tagawa; Naohiro Yoshida; Tsutomu Araki; Taketsugu Tsuchiya; Koutarou Higashi; Junichi Taki; Seigo Kinuya; Kenichi Nakajima; Masatoshi Ikeda; Masanobu Namura; Norihisa Tonami

doi:10.1007/BF03006442

Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma

Takahiro Higuchi, Syoutoku Tagawa, Naohiro Yoshida, Tsutomu Araki, Taketsugu Tsuchiya, Koutarou Higashi, Junichi Taki, Seigo Kinuya, Kenichi Nakajima, Masatoshi Ikeda, Masanobu Namura, Norihisa Tonami

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.

Original language	English
Pages (from-to)	499-501
Number of pages	3
Journal	Annals of nuclear medicine
Volume	17
Issue number	6
DOIs	https://doi.org/10.1007/BF03006442
Publication status	Published - Sep 2003
Externally published	Yes

Keywords

Bronchioloalveolar cell carcinoma
Fluorine-18 fluorodeoxy glucose
Lung cancer
Myocardial perfusion SPECT
Technetium-99m sestamibi

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1007/BF03006442

Fingerprint Dive into the research topics of 'Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma'. Together they form a unique fingerprint.

Cite this

Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma. / Higuchi, Takahiro; Tagawa, Syoutoku; Yoshida, Naohiro; Araki, Tsutomu; Tsuchiya, Taketsugu; Higashi, Koutarou; Taki, Junichi; Kinuya, Seigo; Nakajima, Kenichi; Ikeda, Masatoshi; Namura, Masanobu; Tonami, Norihisa.

In: Annals of nuclear medicine, Vol. 17, No. 6, 09.2003, p. 499-501.

Research output: Contribution to journal › Article › peer-review

Higuchi, Takahiro ; Tagawa, Syoutoku ; Yoshida, Naohiro ; Araki, Tsutomu ; Tsuchiya, Taketsugu ; Higashi, Koutarou ; Taki, Junichi ; Kinuya, Seigo ; Nakajima, Kenichi ; Ikeda, Masatoshi ; Namura, Masanobu ; Tonami, Norihisa. / Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma. In: Annals of nuclear medicine. 2003 ; Vol. 17, No. 6. pp. 499-501.

@article{0d1eedbe570a4e4981e5435ec6ee4a09,

title = "Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma",

abstract = "Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.",

keywords = "Bronchioloalveolar cell carcinoma, Fluorine-18 fluorodeoxy glucose, Lung cancer, Myocardial perfusion SPECT, Technetium-99m sestamibi",

author = "Takahiro Higuchi and Syoutoku Tagawa and Naohiro Yoshida and Tsutomu Araki and Taketsugu Tsuchiya and Koutarou Higashi and Junichi Taki and Seigo Kinuya and Kenichi Nakajima and Masatoshi Ikeda and Masanobu Namura and Norihisa Tonami",

year = "2003",

month = sep,

doi = "10.1007/BF03006442",

language = "English",

volume = "17",

pages = "499--501",

journal = "Annals of Nuclear Medicine",

issn = "0914-7187",

publisher = "Springer Japan",

number = "6",

}

TY - JOUR

T1 - Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma

AU - Higuchi, Takahiro

AU - Tagawa, Syoutoku

AU - Yoshida, Naohiro

AU - Araki, Tsutomu

AU - Tsuchiya, Taketsugu

AU - Higashi, Koutarou

AU - Taki, Junichi

AU - Kinuya, Seigo

AU - Nakajima, Kenichi

AU - Ikeda, Masatoshi

AU - Namura, Masanobu

AU - Tonami, Norihisa

PY - 2003/9

Y1 - 2003/9

N2 - Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.

AB - Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.

KW - Bronchioloalveolar cell carcinoma

KW - Fluorine-18 fluorodeoxy glucose

KW - Lung cancer

KW - Myocardial perfusion SPECT

KW - Technetium-99m sestamibi

UR - http://www.scopus.com/inward/record.url?scp=12444342657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444342657&partnerID=8YFLogxK

U2 - 10.1007/BF03006442

DO - 10.1007/BF03006442

M3 - Article

C2 - 14575387

AN - SCOPUS:12444342657

VL - 17

SP - 499

EP - 501

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 6

ER -

Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this